American Society of Hematology

Figure 2

$Figure 2. MKT-077, an inhibitor of HSP70 family, reduces HSC numbers and increases ROS production in vitro. (A) Representative FACS profiles of CD150+ LSK fractions (upper) and ROS levels in CD150+ LSKs (lower) treated with MKT-077 for 10 days. (B) Absolute cell numbers (upper) and CD150+ LSK cell numbers (lower) in cultures treated with MKT-077 ± NAC for 10 days. Data represent the mean ± SD (n = 4; *P < .05, **P < .01, ***P < .001). (C) Intensity of DCF-DA fluorescence in CD150+ LSK cells (upper) and CD150− LSK cells (lower) treated with MKT-077 ± NAC for 10 days. Data represent the mean ± SD (n = 4; **P < .01, ***P < .001). (D) Colony numbers originating from 300 LSK cells treated with MKT-077 ± NAC for 10 days. Data represent the mean ± SD (n = 3; **P < .01, ***P < .001).$

MKT-077, an inhibitor of HSP70 family, reduces HSC numbers and increases ROS production in vitro. (A) Representative FACS profiles of CD150⁺ LSK fractions (upper) and ROS levels in CD150⁺ LSKs (lower) treated with MKT-077 for 10 days. (B) Absolute cell numbers (upper) and CD150⁺ LSK cell numbers (lower) in cultures treated with MKT-077 ± NAC for 10 days. Data represent the mean ± SD (n = 4; *P < .05, **P < .01, ***P < .001). (C) Intensity of DCF-DA fluorescence in CD150⁺ LSK cells (upper) and CD150⁻ LSK cells (lower) treated with MKT-077 ± NAC for 10 days. Data represent the mean ± SD (n = 4; **P < .01, ***P < .001). (D) Colony numbers originating from 300 LSK cells treated with MKT-077 ± NAC for 10 days. Data represent the mean ± SD (n = 3; **P < .01, ***P < .001).

This Feature Is Available To Subscribers Only